2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110379
    M084 hydrochloride 1992047-63-8 98%
    M084 hydrochloride is a TRPC4/5 channel blocker, with IC50 values of 10.3 μM and 8.2 μM, respectively. M084 hydrochloride has antidepressant and anxiolytic effects.
    M084 hydrochloride
  • HY-11065A
    (iodo-125)-CGP 71872 200402-51-3 98%
    (iodo-125)-CGP 71872 is a iodo-125-labeled CGP 71872 (GABABR1 receptor agonist),containing an azido group that can be photoactivated,and can be used to characterize GABAB receptors.
    (iodo-125)-CGP 71872
  • HY-111006
    (+)-UH 232 95999-12-5 98%
    (+)-UH 232 is a partially selective agonist of the D3 receptor with an intrinsic activity of 0.2-0.4. (+)-UH 232 antagonized quinpirole-induced mitogenesis with a Ki value of 9.4 nM.
    (+)-UH 232
  • HY-111081
    (±)-PPCC 932736-90-8 98%
    (±)-PPCC is a sigma-1 agonist that mainly interacts with sigma-1 receptors with Ki of 1.5 nM. (±)-PPCC has effective anti-amnesia effects in rats with mild or severe cognitive impairment, and can improve the cognitive abilities of rats.
    (±)-PPCC
  • HY-111129
    CP-66713 91896-57-0 98%
    CP-66713 is a selective adenosine A2 receptor antagonist, with Ki of 22 nM. CP-66713 inhibits induction of long-term potentiation of evoked synaptic potentials. CP-66713 can be used in the study of neurological diseases.
    CP-66713
  • HY-111136
    BL-1020 mesylate 916898-61-8 98%
    BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate.
    BL-1020 mesylate
  • HY-111156
    NW-1172 free base 911290-20-5 98%
    NW-1172 (free base) (compound 22b) is a 5-HT3 receptor antagonist with performance-enhancing activity in a delayed matching task in monkeys, with the (R) isomer producing more systematic improvements than the (S) isomer, a difference paralleled by the higher affinity of the (R) enantiomer for the 5-HT3 receptor.
    NW-1172 free base
  • HY-111159
    CP-467688 909576-25-6 98%
    CP-467688 is an orally active retinotoxic agent. CP-467688 induces increased lysosome volume, phagocytosis inhibition and autophagy inhibition in retinal cells. CP-467688 is applicable to the research of retinopathy.
    CP-467688
  • HY-111160
    SKF 83509 90955-43-4 98%
    SKF 83509, a desmethyl analogue of SCH 23390 (HY-19545A), is a selective dopamine D1 antagonist with a Ki of 70.2 nM. SKF 83509 has no activity at dopamine D2 receptors.
    SKF 83509
  • HY-111162
    GSK494581A 909416-67-7 98%
    GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55.
    GSK494581A
  • HY-111210
    Pridopidine hydrochloride 882737-42-0 98%
    Pridopidine (ACR16) hydrochloride, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with Ki between 70 and 80 nM, which is ~100-fold higher than its affinity toward D2R.
    Pridopidine hydrochloride
  • HY-111256
    A-850002 869802-73-3 98%
    A-850002 is a metabotropic glutamate receptor (mGluR) antagonist (IC50=27 nM) that significantly attenuates spontaneous pain behavior after skin incision in rats. A-850002 can be used for analgesia research.
    A-850002
  • HY-111291
    ICI 169369 free base 85273-95-6 98%
    ICI 169369 (free base) is an orally active, selective and non-competitive antagonist against 5HT receptor. ICI 169369 (free base) blunts the vasopressin (AVP), but not the ACTH, prolactin or growth hormone reponses to insulin-induced hypoglycaemia. ICI 169369 (free base) blocks centrally mediated 5-HT responses and lowers portal pressure in portal hypertensive rats.
    ICI 169369 free base
  • HY-111479
    Amibegron 121524-08-1 98%
    Amibegron is a selective β3-adrenoceptor agonist, with an EC50 of 3.5 nM for β-adrenoceptor in rat colon; Amibegron has anxiolytic and antidepressant activity.
    Amibegron
  • HY-112013
    Isodimethoate 3344-11-4 98%
    Isodimethoate is a thermal decomposition product of Dimethoate (HY-B1946). Isodimethoate is a direct anticholinesterase agent and shows an inhibition to human red blood cell acetylcholinesterase (AChE).
    Isodimethoate
  • HY-112015
    Deschlorohaloperidol 3109-12-4 98%
    Deschlorohaloperidol (compound 8h) is an analogue of Haloperidol (HY-14538). Haloperidol is a dopamine D2 receptor (D2R) antagonist for schizophrenia.
    Deschlorohaloperidol
  • HY-112282
    BI-1408 2231075-94-6 98%
    BI-1408 is a potent γ secretase modulator with an IC50 of 0.04 μM for Aβ42.
    BI-1408
  • HY-112330
    4-Cyano-3-methylisoquinoline 161468-32-2 98%
    4-Cyano-3-methylisoquinoline is an inhibitor for protein kinase A (PKA) with an IC50 of micromolar level. 4-Cyano-3-methylisoquinoline reverses morphine tolerance in mouse model.
    4-Cyano-3-methylisoquinoline
  • HY-112464
    PKR Inhibitor, negative control 852547-30-9 98%
    PKR Inhibitor, negative control is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitor, which can be used as a negative control. PKR Inhibitor, negative control can also inhibit LK-induced neuronal death, exhibiting significant neuroprotective effects.
    PKR Inhibitor, negative control
  • HY-112817
    8-Oxo-dGTP 139307-94-1 98%
    8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms.
    8-Oxo-dGTP
Cat. No. Product Name / Synonyms Application Reactivity